- Home
- NLSP vs BGLC Comparison
NLSP vs BGLC Comparison
Compare NLSP & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- BGLC
- Stock Information
- Founded
- NLSP 2015
- BGLC 2017
- Country
- NLSP Switzerland
- BGLC Malaysia
- Employees
- NLSP N/A
- BGLC N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- BGLC Medical Specialities
- Sector
- NLSP Health Care
- BGLC Health Care
- Exchange
- NLSP Nasdaq
- BGLC Nasdaq
- Market Cap
- NLSP 243.8M
- BGLC 7.6M
- IPO Year
- NLSP 2021
- BGLC N/A
- Fundamental
- Price
- NLSP $4.96
- BGLC $0.38
- Analyst Decision
- NLSP
- BGLC
- Analyst Count
- NLSP 0
- BGLC 0
- Target Price
- NLSP N/A
- BGLC N/A
- AVG Volume (30 Days)
- NLSP 34.6K
- BGLC 116.1K
- Earning Date
- NLSP 11-01-2024
- BGLC 11-20-2024
- Dividend Yield
- NLSP N/A
- BGLC N/A
- EPS Growth
- NLSP N/A
- BGLC N/A
- EPS
- NLSP N/A
- BGLC N/A
- Revenue
- NLSP N/A
- BGLC $9,183,168.00
- Revenue This Year
- NLSP N/A
- BGLC N/A
- Revenue Next Year
- NLSP N/A
- BGLC N/A
- P/E Ratio
- NLSP N/A
- BGLC N/A
- Revenue Growth
- NLSP N/A
- BGLC N/A
- 52 Week Low
- NLSP $4.08
- BGLC $0.31
- 52 Week High
- NLSP $29.68
- BGLC $3.39
- Technical
- Relative Strength Index (RSI)
- NLSP 46.37
- BGLC 41.00
- Support Level
- NLSP $4.52
- BGLC $0.38
- Resistance Level
- NLSP $5.64
- BGLC $0.49
- Average True Range (ATR)
- NLSP 0.48
- BGLC 0.02
- MACD
- NLSP 0.07
- BGLC -0.00
- Stochastic Oscillator
- NLSP 55.44
- BGLC 32.66
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.